Table 1 Application of MSC-derived exsomes in liver diseases
From: Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases
MSCs | miRNA/target genes | Animal strain | Disease model | Functions | Ref |
|---|---|---|---|---|---|
hucMSCs | Unknown | Kunming mouse | CCl4-induced liver fibrosis | Inhibit hepatocytes EMT and collagen production through inactivating TGF-β1/Smad pathway | |
CP-MSCs | miR-125b/Smo | Sprague–Dawley rat | CCl4-induced liver fibrosis | Impede Hh signaling activation in HSCs by inhibiting Smo expression | |
AD-MSC-122 | miR-122/P4HA1, IGF1R | C57BL/6 mouse | CCl4-induced liver fibrosis | Reduce the proliferation and activation of HSCs more effectively than naïve AD-MSCs | UPD |
HuES9.E1 MSCs | Unknown | C57BL/6 mouse | CCl4, APAP or H2O2- induced liver injury | Increase hepatocyte proliferation by upregulating proliferation proteins and anti-apoptosis gene | |
AD-MSCs | Unknown | C57BL/6 mouse | Con A-induced acute liver failure | Reduce serum ALT and AST levels and proinflammatory cytokines production | UPD |
AD-MSCs | Unknown | Fischer-344 rat | Rat N1S1 cell-bearing orthotopic HCC model | Suppress HCC by promoting NKT cell anti-tumor responses | |
AD-MSC-122 | miR-122/CCNG1, ADAM10, etc. | BALB/c nu/nu mouse | HepG2 cell xenograft nude mice | Sensitize HCC to 5-FU or sorafenib therapy |
